<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00727636</url>
  </required_header>
  <id_info>
    <org_study_id>07-09-0344</org_study_id>
    <nct_id>NCT00727636</nct_id>
  </id_info>
  <brief_title>Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy</brief_title>
  <acronym>HPV</acronym>
  <official_title>Pilot Study of Immunogenicity and Tolerability to the Quadrivalent Human Papillomavirus Virus-like Particle (VLP) Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy Compared to Healthy Children and Youth Adult Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many IBD patients take immunosuppressive agents and we are uncertain as to their capacity to
      mount a truly protective response after vaccination. If IBD patients do not have an adequate
      immunological response, they may need to increase the dosage or get booster shots. Many
      clinicians who treat patients with autoimmune diseases are asking if the vaccine is safe and
      effective. Thus, this study has important clinical and public health significance because
      more than one million people in the United States have been diagnosed with IBD.

      There is not much studied about HPV and immunocompromised patients. Research on healthy women
      who were immunized with a set of three HPV vaccines demonstrated significantly increased
      antibody titers. In addition, they had significantly reduced HPV incident and persistent
      infection and HPV-related disease (cervical, vulvar, and vaginal cancers, cervical
      intraepithelial neoplasia, genital warts) through five years of follow-up compared to
      controls who received a placebo. The HPV vaccine was well tolerated without significant side
      effects.

      The aims of this research are to measure the immune response in 9-26 year old IBD patients
      who are on immunosuppressive agents after receiving the HPV vaccine compared with historical
      controls. We will also evaluate the number and type of vaccine-associated adverse events as
      well as the disease activity and flare-ups that occur after each dose of vaccine. We
      hypothesize that IBD patients on immunosuppressive therapy will have have a similar immune
      response to HPV types 6, 11, 16 and 18 at one month postdose 3 compared to healthy
      age-matched historical controls.

      The patient population includes IBD patients who are on immunosuppressive medications.
      Recruiting approximately 100 patients will provide adequate power for the study. A blood
      sample will be taken from all IBD patients to evaluate baseline antibody levels and markers
      (e.g., ESR, CBC, albumin) before or immediately after immunization with the HPV vaccine. Lab
      tests will be redrawn at 7 months to evaluate the level of antibody titers and follow the
      markers. During the study, we will track basic laboratory measures, disease status by using
      the Pediatric Crohn's Disease Active Index or Harvey-Bradshaw Index for UC, side effects from
      the vaccinations, and other adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Titer to HPV 6</measure>
    <time_frame>Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Titer to HPV 11</measure>
    <time_frame>Month 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Titers to HPV 16</measure>
    <time_frame>Month 7</time_frame>
    <description>Geometric mean titer (95% CI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Titer to HPV 18</measure>
    <time_frame>Month 7</time_frame>
    <description>Geometric mean titer (95%CI)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Gardasil vaccine - Prospective Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective study participants received the Gardasil vaccine during the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective Study</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Retrospective study participants had blood drawn in the study after they had received the Gardasil vaccine from their primary medical provider</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil vaccine</intervention_name>
    <description>standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6</description>
    <arm_group_label>Gardasil vaccine - Prospective Study</arm_group_label>
    <other_name>Gardasil, HPV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Crohn's disease, ulcerative colitis, or indeterminate colitis diagnosed by standard
             clinical, radiographic, endoscopic, and histologic criteria.

          2. Actively followed by a physician at the Children's' Hospital gastroenterology (GI) or
             IBD Center, or patient is referred by local clinic or hospital for our study.

          3. Female gender

          4. Age 9-26 years

          5. Patient (18 years old) or parent is willing to provide informed consent.

          6. Is currently on an immunomodulator and/or TNF inhibitor for ≥ 30 days prior to
             enrollment. Patients may also be using prednisone or aminosalicylates in addition to
             the immunomodulator or TNF inhibitor. Standard concomitant medications (e.g.
             antibiotics, antihistamines, acetaminophen) will be allowed

        Exclusion Criteria:

          1. Male gender

          2. Unwilling to provide consent

          3. New immunomodulator added within the last 30 days, and was not previously on any
             immunomodulator

          4. History of bleeding disorder that would make hematoma likely (e.g., hemophilia, von
             Willebrand's disease) or on anti-coagulation therapy (certain cases may be allowed;
             each case will be assessed by study doctor)

          5. Hypersensitivity to the ingredients/components of the vaccine (e.g., aluminum, yeast)

          6. Known pregnancy or positive pregnancy test. We will obtain a urinary pregnancy test
             before each dose of the vaccine is administered. Subjects participating will be
             informed during the consent/assent procedures that the safety of this vaccine has not
             been proven in pregnant women, and will be advised not to become pregnant during the
             study and counseled according to the guidelines of the Children's Hospital IRB.

          7. Previously received HPV vaccination.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athos Bousvaros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denise L Jacobson, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>August 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2008</study_first_posted>
  <results_first_submitted>May 3, 2011</results_first_submitted>
  <results_first_submitted_qc>May 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2011</results_first_posted>
  <last_update_submitted>May 3, 2011</last_update_submitted>
  <last_update_submitted_qc>May 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Athos Bousvaros, MD</name_title>
    <organization>Children's Hospital Boston</organization>
  </responsible_party>
  <keyword>inflammatory bowel disease (IBD)</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>safety</keyword>
  <keyword>HPV</keyword>
  <keyword>Gardasil</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Location - Children’s Hospital Boston, including Waltham Infusion Center, and Maine Medical Center. Patients were recruited during a scheduled clinical or Remicade infusion visit, a hospital admission, by contact through mail followed by a phone call, or through referral from local hospitals. Recruitment period -April 2008 through April 2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Prospective Cohort</title>
          <description>Received Gardasil as part of study</description>
        </group>
        <group group_id="P2">
          <title>Retrospective Cohort</title>
          <description>Patients received Gardasil vaccine from their primary medical provider. They had blood drawn for the study after they completed the vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prospective Cohort</title>
          <description>Received Gardasil as part of study</description>
        </group>
        <group group_id="B2">
          <title>Retrospective Cohort</title>
          <description>Patients received Gardasil vaccine from their primary medical provider. They had blood drawn for the study after they completed the vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.9" spread="3.1"/>
                    <measurement group_id="B2" value="18.9" spread="3.5"/>
                    <measurement group_id="B3" value="16.1" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Titer to HPV 6</title>
        <time_frame>Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prospective Cohort</title>
            <description>Received Gardasil as part of study</description>
          </group>
          <group group_id="O2">
            <title>Retrospective Cohort</title>
            <description>Patients received Gardasil vaccine from their primary medical provider. They had blood drawn for the study after they completed the vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titer to HPV 6</title>
          <units>milli-Merck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1079.9" lower_limit="783" upper_limit="1489.3"/>
                    <measurement group_id="O2" value="173.4" lower_limit="91.3" upper_limit="329.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Titer to HPV 11</title>
        <time_frame>Month 7</time_frame>
        <population>Number of participants who completed all vaccine doses</population>
        <group_list>
          <group group_id="O1">
            <title>Prospective Cohort</title>
            <description>Received Gardasil as part of study</description>
          </group>
          <group group_id="O2">
            <title>Retrospective Cohort</title>
            <description>Patients received Gardasil vaccine from their primary medical provider. They had blood drawn for the study after they completed the vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titer to HPV 11</title>
          <population>Number of participants who completed all vaccine doses</population>
          <units>milli-Merck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1681.8" lower_limit="1189.9" upper_limit="2377.2"/>
                    <measurement group_id="O2" value="267.3" lower_limit="122.4" upper_limit="583.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Titers to HPV 16</title>
        <description>Geometric mean titer (95% CI)</description>
        <time_frame>Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prospective Cohort</title>
            <description>Received Gardasil as part of study</description>
          </group>
          <group group_id="O2">
            <title>Retrospective Cohort</title>
            <description>Patients received Gardasil vaccine from their primary medical provider. They had blood drawn for the study after they completed the vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titers to HPV 16</title>
          <description>Geometric mean titer (95% CI)</description>
          <units>milli-Merck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3975.1" lower_limit="2492.2" upper_limit="6340.6"/>
                    <measurement group_id="O2" value="802.7" lower_limit="391.1" upper_limit="1676.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Titer to HPV 18</title>
        <description>Geometric mean titer (95%CI)</description>
        <time_frame>Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prospective Cohort</title>
            <description>Received Gardasil as part of study</description>
          </group>
          <group group_id="O2">
            <title>Retrospective Cohort</title>
            <description>Patients received Gardasil vaccine from their primary medical provider. They had blood drawn for the study after they completed the vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titer to HPV 18</title>
          <description>Geometric mean titer (95%CI)</description>
          <units>milli-Merck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="857.6" lower_limit="472.4" upper_limit="1556.6"/>
                    <measurement group_id="O2" value="79.5" lower_limit="26.3" upper_limit="240.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the 1st dose of vaccine until 1 month after the 3rd dose of vaccine</time_frame>
      <desc>Adverse events were only evaluated in the Prospective Study patients. The Retrospective Study patients were not given the vaccine as part of this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Prospective Cohort</title>
          <description>Received Gardasil as part of study</description>
        </group>
        <group group_id="E2">
          <title>Retrospective Cohort</title>
          <description>Patients received Gardasil vaccine from their primary medical provider. They had blood drawn for the study after they completed the vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Admitted to hospital</sub_title>
                <description>exacerbation of inflammatory bowel disease</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Admitted to hospital</sub_title>
                <description>Endometriosis with an ovarian torsion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Admitted to hospital</sub_title>
                <description>pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Went to emergency department</sub_title>
                <description>Sinus pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal bleeding and diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling and severe pain in arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>leg pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma related symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash on their chin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Athos Bousvaros</name_or_title>
      <organization>Children's Hospital Boston</organization>
      <phone>617-355-2962</phone>
      <email>athos.bousvaros@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

